帕米膦酸二钠与氯甲磷酸二钠治疗晚期肿瘤骨转移的疗效观察

目的 为了比较帕米膦酸二钠与氯甲膦酸二钠对骨转移所致高血钙和骨痛的治疗作用。方法将收治的有溶骨性骨转移病灶的７８例随机分为两组，治疗组４０例，采用帕米膦酸二钠０ｍｇ／天，共用１天；对照组３８例，采用氯甲膦酸二钠３００ｍｇ／天，共用５天。两均加入５％葡萄糖溶液５００ｍｌ中静脉滴注５个小时，血钙下降率和骨痛缓解率作为评价指标。结果 治疗组血钙血高者１３例，治疗后第７天１１例血钙降至正常，下降率８４．     

帕米膦酸二钠与氯甲磷酸二钠治疗晚期肿瘤骨转移的疗效观察

目的　为了比较帕米膦酸二钠与氯甲膦酸二钠对骨转移所致高血钙和骨痛的治疗作用。方法将收治的有溶骨性骨转移病灶的７８ 例随机分为两组,治疗组４０ 例,采用帕米膦酸二钠３０ ｍｇ／ 天,共用１ 天;对照组３８ 例,采用氯甲膦酸二钠３００ ｍｇ／ 天,共用５ 天。两者均加入５ ％ 葡萄糖溶液５００ ｍｌ 中静脉滴注４ 个小时,血钙下降率和骨痛缓解率作为评价指标。结果　治疗组血钙升高者１３ 例,治疗后第７ 天１１ 例血钙降至正常,下降率８４．６ ％ 。对照组血钙升高者５ 例,治疗后３ 例降至正常,下降率６０ ％ 。疼痛缓解方面,治疗组与对照组治疗前均有骨痛,治疗后分别有２５ 例和１５ 例缓解,疼痛缓解率分别为６２．５ ％ 和３９．６％ 。治疗组血钙下降率和疼痛缓解率均高于对照组,但两者之间差异无显著性（ Ｐ＞ ０．０５） 。两组病人在用药过程中均未见严重不良反应。结论　帕米膦酸二钠与氯甲膦酸二钠均为治疗晚期肿瘤骨转移所致高血钙和骨痛的有效药物,临床使用方便,病人耐受性好。     

帕米膦酸二钠治疗恶性肿瘤骨转移的临床研究

目的进一步评价国产帕米膦酸二钠对肿瘤骨转移所致骨痛和高血钙的治疗作用,并观察该药的不良反应。方法４２例有溶骨性骨转移病灶的晚期肿瘤病人,接受５９个疗程帕米膦酸二钠（９０ｍｇ／ｄ,共用１天;或３０ｍｇ／ｄ,共用３天）治疗。结果帕米膦酸二钠对癌性骨痛的有效率为７１．２％,活动能力改善率为６７．３％;血钙升高者４例,经治疗后其血钙水平均降至正常;用药过程中均未见严重不良反应。结论帕米膦酸二钠是一种治疗恶性肿瘤骨转移引起的骨痛和高血钙的有效药物,病人耐受良好     

帕米膦酸二钠联合放疗治疗骨转移癌的疗效观察

目的：观察帕米膦酸二钠（博宁）联合放射治疗骨转移癌所致骨痛和高血钙的疗效。方法：对照组30例骨转移癌患者行单纯常规放疗，DT30GY／3GY／10f；治疗组34例骨转移癌患者行放射治疗前给予帕米膦酸二钠90mg加入生理盐水中缓慢静脉滴注4—6h（可分为2天用药），接着行放射治疗，照射方法同对照组，每4周为1个周期，至少连用6个周期。以放疗结束时及结束后6个月的疼痛缓解率及血钙下降率作为评价标准。结果：治疗组疼痛缓解率和血钙下降率与对照组比较无明显差异；结束6个月后治疗组疼痛缓解率和血钙下降率均高于对照组（P〈0．05）结论：帕米膦酸二钠（博宁）联合放疗可显著缓解骨转移引起的疼痛，降低高血钙，临床应用方便，患者耐受性好。     

帕米膦酸钠与氯甲膦酸二钠治疗骨转移性疼痛的临床对照观察

目的：对照观察帕米膦酸钠（阿可达Ａｒｅｄｉａ）与氯甲膦酸二钠（骨膦Ｃｌｏｄｒｏｎａｔｅ）对恶性肿瘤骨转移性疼痛的止痛效果。方法：将４７例伴有骨痛的恶性肿瘤骨转移患者分为观察组，阿可达６０～９０ｍｇ静滴，四周重复；对照组，骨膦３０ｍｇ／日静滴共５天，继而口服骨膦胶囊８００ｍｇＴｉｄ共２５天。结果：止痛有效率，观察组为８８．７％，对照组为６１．９％；活动能力改善率：观察组为８４．６％，对照组为５７．１     

帕米膦酸二钠治疗32例恶性肿瘤骨痛的临床观察

目的:采用帕米膦酸二钠治疗32例恶性肿瘤骨痛进行临床观察。方法:32例恶性肿瘤骨转移及多发性骨髓瘤患者,疼痛Ⅰ-Ⅲ级。静滴帕米膦酸二钠60mg,3周重复,共用2-4次。结果:止痛有效率62．5％ (20／32),活动能力改善有效率65．6％(21／32)。结论:帕米膦酸二钠治疗恶性肿瘤骨转移性疼痛疗效确切,使用安全。     

唑来膦酸与帕米膦酸二钠治疗肺癌骨转移疼痛的对比研究

为了评价唑来膦酸注射液治疗肺癌骨转移所致骨痛的疗效及安全性,将临床确诊的肺癌骨转移患者50例随机分为唑来膦酸组25例和帕米膦酸二钠组25例.结果:唑来膦酸组和帕米膦酸二钠组治疗骨痛总有效率为76%(19/25)和72%(18/25),差异无统计学意义,P=0.798.止痛起效时间:唑来膦酸组1～11d(中位时间5d),帕米膦酸二钠组2～13d(中位时间5d),差异无统计学意义,P=0.702.止痛疗效维持时间:唑来膦酸组2～32d(中位时间24d),帕米膦酸二钠组1～29d(中位时间23d),差异无统计学意义,P=0.509.初步研究结果提示,唑来膦酸注射液治疗肺癌骨转移疼痛疗效确切,与帕米膦酸二钠相比疗效和不良反应相似.     

唑来膦酸与帕米膦酸二钠治疗乳腺癌骨转移性疼痛的近期疗效观察

目的 评价唑来膦酸与帕米膦酸二钠治疗乳腺癌骨转移性疼痛的近期疗效及不良反应。方法 所有病例均为乳腺癌骨转移患者，其中唑来膦酸组29例，帕米膦酸二钠组25例。给药方法：唑来膦酸4mg＋生理盐水50ml静脉滴注15min；帕米膦酸二钠60mg＋生理盐水500ml静脉滴注4h；均每4周1次，共3次。记录治疗效果及不良反应。结果 疼痛缓解情况：唑来膦酸组完全缓解（CR）15例（51．7％），部分缓解（PR）9例（31．0％），临床获益[CR＋PR＋轻度缓解（MR）]93．0％；帕米膦酸二钠组CR11例（44．0％），PR7例（28．0％），临床获益88．0％。主要不良反应为发热、感冒样症状、低钙血症。结论 唑来膦酸与帕米膦酸二钠对乳腺癌转移性骨痛有较好的疗效；两药的治疗效果及不良反应相似，但唑来膦酸使用更为方便。     

帕米膦酸二钠治疗32例恶性肿瘤骨痛的临床观察

目的:采用帕米膦酸二钠治疗32例恶性肿瘤骨痛进行临床观察.方法:32例恶性肿瘤骨转移及多发性骨髓瘤患者,疼痛Ⅰ～Ⅲ级.静滴帕米膦酸二钠60mg,3周重复,共用2～4次.结果:止痛有效率62.5%(20/32),活动能力改善有效率65.6%(21/32).结论:帕米膦酸二钠治疗恶性肿瘤骨转移性疼痛疗效确切,使用安全.     

帕米膦酸二钠治疗28例恶性骨痛的临床观察

目的：对帕米膦酸二钠治疗28例恶性肿瘤骨痛进行临床观察。方法：28例恶性骨转移癌及多发性骨髓瘤患者,疼痛Ⅰ～Ⅲ,静滴帕米膦酸二钠60mg,2周后重复,共用2～4次。结果：止痛有效率60．7％（17／28）,活动能力改善有效率53．6％（15／28）。结论帕米膦酸二钠治疗恶性肿瘤溶骨性转移性疼痛疗效确实,不良反应轻微。     

Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy

Data on the long-term treatment of myeloma bone disease with bisphosphonates are scanty. In a prospective pilot trial we evaluated the effect of long-term parenteral administration of dichloromethylene bisphosphonate (Clodronate), in addition to standard chemotherapy, in 30 patients with active myeloma bone disease. Patients were treated with a mean of 4 courses (range 2-8) of Clodronate: 300 mg/day i.v. for seven days followed by 100 mg/day i.m. for 10 days, administered at a mean interval of 4 months (range 3-6). The median follow-up was 24 months (range 8-36). Clodronate reduced bone pain rapidly and significantly, and reduced the mean values of the biochemical indices of bone resorption to within normal limits; these effects were maintained throughout the follow-up. In three hypercalcemic episodes serum calcium became normal after 2-5 days of treatment with Clodronate. No toxic or side effects were noticed. The occurrence of skeletal morbidity in patients treated with Clodronate was compared with that observed in the control group of myeloma patients (p less than 0.001) in severe bone pain as well as in the incidence of new osteolytic lesions and pathological fractures (p less than 0.001). Supportive Clodronate therapy contributes significantly in controlling the progression of myeloma bone disease.     

国产氯屈膦酸二钠治疗恶性肿瘤骨转移疼痛的临床观察

目的：评价国产氯屈膦酸二钠治疗恶性肿瘤骨转移疼痛的疗效及其安全性。方法：将56例伴有骨痛的恶性肿瘤骨转移患者随机分为试药组(国产氯屈膦酸二钠组)和对照组(骨膦组)。结果：止痛有效率试药组为82．8％,对照组为85.2％;活动改善率试验组为65．4％,对照组为66．7％。经统计学处理两组间止痛有效率和活动能力改善率均无显著差异,均毒副作用轻微。结论：国产氯屈膦酸二钠能较好地控制骨转移癌性疼痛,改善活动能力,安全可靠,值得临床推广应用。     

博宁联合化疗治疗骨转移癌所致疼痛的疗效观察

目的：选择理想的治疗骨转移癌所致疼痛的方法。方法：以博宁联合化疗或以^153Sm—EDTMP内照射联合化疗治疗52例骨转移癌。结果：治疗组总有效率为84．00％，对照组总有效率为59．26％。结论：治疗骨转移癌所致的骨痛，以博宁联合化疗为主的方法优于^153Sm—EDTMP内照射联合化疗的方法。     

Osteoclast inhibition by pamidronate in metastatic prostate cancer: a preliminary study

Twenty five hormone manipulated patients with prostate cancer and metastatic bone disease, treated at least 6/12 previously by hormone manipulation, were given intravenous infusions of Disodium Pamidronate (APD) over a 6 month period. Patients received 30 mg weekly for 4 weeks then twice monthly for 5 months. No other treatment was administered during study. Eleven of 17 patients with pain at the start of the study were pain free at the end. Fasting morning calcium excretion and serum osteocalcin fell significantly with Pamidronate (P less than 0.0001) and urine hydroxyproline was lowered in 13/20 evaluable patients at 6 months. Alkaline phosphatase fell in a proportion of patients and five of 17 patients with previously progressive bone scans stabilised (4) or regressed (1) on treatment. Rising acid phosphatase levels were also lowered in five patients. It is concluded that Pamidronate may be effective in palliating bone pain in some patients and has a stabilising influence on abnormally high bone turnover in metastatic prostate cancer. Further controlled studies of the compound are now warranted.     

Treatment of malignant hypercalcaemia with clodronate

We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppressed for the duration of treatment, but recurred promptly when treatment was stopped. Clodronate may be a useful measure for controlling hypercalcaemia and osteolysis in patients with carcinoma.     

氯屈膦酸二钠治疗恶性肿瘤骨转移引起疼痛的疗效观察

目的 :观察国产氯屈膦酸二钠 (洛屈 )治疗恶性肿瘤骨转移引起疼痛的临床效果。方法 :共收治有溶骨性骨转移病灶的患者 4 6例 ,采用氯屈膦酸二钠 30 0mg/d ,静脉滴入 ,连用 5d ,3周为 1个疗程。结果 :止痛显效 18例 (39 1% ) ,有效 19例 (4 1 3% ) ,总有效率 80 4 % ,无效 9例。获效时间 5～ 30d ,有效病例 71 6 %在 2周内获效。 4 6例患者在用药过程中未见有严重不良反应 ,耐受性良好。结论 :国产氯屈膦酸二钠是一种治疗恶性肿瘤骨转移引起疼痛的有效药物 ,临床使用方便 ,患者耐受性良好     

帕米膦酸二钠联合放疗治疗骨转移癌的疗效观察

目的：观察帕米膦酸二钠（博宁）联合放射治疗对骨转移癌所致高血钙和骨痛的治疗作用。方法：在对65例骨转移患者放射治疗前将帕米膦酸二钠90mg加入5％葡萄糖溶液500ml中,静脉滴注6h,每月1次,共6次,对照组65例行单纯放疗。剂量为DT30Gy,每周5次,共2周。以放疗结束时及结束后6个月的疼痛缓解率、血钙下降率作为评价指标。结果：放疗结束时,治疗组疼痛缓解率和血钙下降率与对照组无明显差异;结束6个月后,治疗组疼痛率和血钙下降率均高于对照组（P＜0．05）。不良反应轻。结论：应用帕米膦酸二钠90mg,每月1次,共6次,配合放疗,可显著缓解骨转移引起的疼痛,降低高血钙,临床应用方便,患者耐受性好。     

放射性核素氯化锶联合99Tc-亚甲基二膦酸盐治疗前列腺癌骨转移患者的疗效观察(附39例)

目的:探讨99Tc-亚甲基二膦酸盐与放射性核素氯化锶联合治疗前列腺癌骨转移患者的疗效及对近期预后的影响。方法:选取2014年2月至2016年4月我院77例前列腺癌骨转移患者,通过随机数字表法分为对照组(n=38)与研究组(n=39)。对照组予以放射性核素氯化锶治疗,研究组于对照组基础上联合99Tc-亚甲基二膦酸盐治疗,治疗后随访12个月。统计比较两组骨痛治疗效果、骨转移治疗效果、不良反应发生率、治疗后6个月及12个月疾病复发率、治疗前后生活质量(SF-36)评分。结果:研究组骨痛治疗效果优于对照组(P<0.05),总有效率研究组92.31%(36/39)高于对照组63.16%(24/38)(P<0.05);研究组骨转移治疗效果优于对照组(P<0.05),总有效率研究组82.05%(32/39)高于对照组39.47%(15/38)(P<0.05);研究组不良反应发生率12.82%(5/39)与对照组5.26%(2/38)对比无明显差异(P>0.05);研究组治疗后6个月、12个月疾病复发率0.00%(0/39)、2.56%(1/39)低于对照组15.79%(6/38)、23.68%(9/38)(P<0.05);研究组治疗后躯体疼痛、生理机能、生理职能、情感职能、精神健康、社会功能等SF-36评分均高于对照组(P<0.05)。结论:予以99Tc-亚甲基二膦酸盐与放射性核素氯化锶联合治疗前列腺癌骨转移患者疗效显著,可有效缓解骨痛及骨转移,降低复发率,提升生活质量,改善近期预后效果,且安全性较高。     

USe of Clodronate in Multiple Myeloma

Multiple myeloma is characterized by bone disease including osteoporosis, osteolytic lesions, pathological fractures and hypercalcaemia leading to pain, immobilization and decrease in the quality of life. Clodronate. a bisphosphonate, has been shown to be effective in the treatment of hypercalcaemia in patients with multiple myeloma. In addition, clodronate reduces the progression of osteolytic lesions and the amount of vertebral fractures and may also relieve pain in these patients. Recent studies suggest that oral clodronate should be considered in the adjunctive treatment of all patients with active multiple myeloma independently of the presence of bone lesions at diagnosis. Due to its safety and efficacy, clodronate seems to have gained an important role in the management of patients with multiple myeloma.